ProFound AI™ Platform Featured at Journées Francophones de Radiologie Congress in Paris
iCAD to Showcase Entire
ProFound AI Platform, including its Solutions for 2D Mammography and Digital
Breast Tomosynthesis in Paris at Medical Conference
NASHUA, N.H. and PARIS – October 7, 2019 – iCAD, Inc. (NASDAQ: ICAD), a global medical
technology leader providing innovative cancer detection and therapy solutions,
today announced the full ProFound AI™ platform will be featured in the iCAD
exhibition booth (#226A) at the Journées Francophones de Radiologie (JFR) Congress
in Paris from October 11-14, 2019. The ProFound AI Platform includes both ProFound
AI™ for Digital Breast Tomosynthesis (DBT), which was CE marked in March 2018
and FDA cleared in December 2018, as well as ProFound AI™ for 2D Mammography, which
was CE marked in July 2019.
“ProFound AI for DBT is the first and only artificial intelligence
software for DBT that is clinically proven to enhance breast cancer screening,
reduce false positives and unnecessary recalls, and cut reading time for
radiologists by more than half. Its use continues to increase in France, as
well as a growing number of countries worldwide, as more clinicians discover
the benefits it offers,” said Michael Klein, Chairman and CEO of iCAD. “This
revolutionary technology improves radiologists’ confidence and optimizes
workflow and operational efficiencies, even with the most challenging cases to
read, such as those with dense breasts.”
ProFound AI for 2D Mammography and ProFound AI
for DBT are high-performing workflow solutions featuring
the latest in deep-learning artificial intelligence capabilities. Trained with
one of the largest available datasets, the software
is designed to rapidly and accurately
analyze each image and provide radiologists with
key information, such as Certainty of Finding lesion and Case Scores,
which assists in clinical decision-making and prioritizing caseloads. It also features the latest in deep-learning
artificial intelligence, which allows for continuously improved performance via
ongoing updates.
Positive clinical data from a large reader
study involving ProFound AI for DBT were recently published in Radiology: Artificial Intelligence. According to the study, ProFound AI for DBT improved
radiologist sensitivity by 8 percent, reduced unnecessary patient recall rates
by 7.2 percent, and slashed reading time for
radiologists by 52.7 percent.1Additionally,
ProFound AI cut reading time by up to 57.4 percent for radiologists reading
cases with dense breasts.2
“The arrival of ProFound AI marks a real technological
advancement in the development of breast cancer detection tools. I use ProFound
AI in my daily practice, and it helps me in my diagnostic decision making,”
said Corinne Balleyguier, MD, PhD, radiologist at
Gustave Roussy Cancer Campus, Villejuif, France. “In the beginning, I was
skeptical about how AI could help me, but I quickly understood the undeniable
assistance ProFound AI could bring, especially with subtle lesions and complex
cases.”
iCAD will also be hosting a symposium
during the JFR congress, titled “AI- The New Partner for Radiologists in Breast
Cancer Detection” on Sunday, October 13, at 12:30 in Conference Room #251, featuring
Dr. Balleyguier.
ProFound AI for DBT was FDA-cleared, CE marked, and Health Canada
licensed in 2018. ProFound AI for 2D Mammography was CE marked in July 2019. For more information, visit www.icadmed.com.
References:
- Conant, E. et al. (2019). Improving
Accuracy and Efficiency with Concurrent Use of Artificial Intelligence
for Digital Breast Tomosynthesis. Radiology: Artificial Intelligence. 1 (4).
Accessed via https://pubs.rsna.org/doi/10.1148/ryai.2019180096 - Hoffmeister, J.
(2018). Artificial Intelligence for Digital Breast Tomosynthesis – Reader Study
Results. [White paper]. Accessed via https://www.icadmed.com/assets/dmm253-reader-studies-results-rev-a.pdf
About iCAD, Inc.
Headquartered in Nashua, NH, iCAD is a global
medical technology leader providing innovative cancer detection and therapy
solutions. For more information, visit www.icadmed.com.
“Safe Harbor” Statement under the Private Securities
Litigation Reform Act of 1995
Certain statements contained in this News Release constitute
“forward-looking statements” within the meaning of the Private Securities
Litigation Reform Act of 1995. Such forward-looking statements involve a number
of known and unknown risks, uncertainties and other factors which may cause the
actual results, performance or achievements of the Company to be materially
different from any future results, performance or achievements expressed or
implied by such forward-looking statements. Such factors include, but are not
limited, to the Company’s ability to defend itself in litigation matters, to
achieve business and strategic objectives, the risks of uncertainty of patent
protection, the impact of supply and manufacturing constraints or difficulties,
uncertainty of future sales levels, protection of patents and other proprietary
rights, the impact of supply and manufacturing constraints or difficulties,
product market acceptance, possible technological obsolescence of products,
increased competition, litigation and/or government regulation, changes in
Medicare or other reimbursement policies, risks relating to our existing and
future debt obligations, competitive factors, the effects of a decline in the
economy or markets served by the Company; and other risks detailed in the
Company’s filings with the Securities and Exchange Commission. The words
“believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,”
“anticipate,” “likely,” “seek,” and similar expressions identify
forward-looking statements. Readers are cautioned not to place undue reliance
on those forward-looking statements, which speak only as of the date the
statement was made. The Company is under no obligation to provide any updates
to any information contained in this release. For additional disclosure
regarding these and other risks faced by iCAD, please see the disclosure
contained in our public filings with the Securities and Exchange Commission,
available on the Investors section of our website at https://www.icadmed.com and on the SEC’s website
at http://www.sec.gov.
Contacts:
Media inquiries:
Jessica Burns, iCAD
+1-201-423-4492
FP2COM
Florence
Portejoie
Tel :
+ 33 6 07 76 82 83 France
Investor
Relations:
LifeSci Advisors, on behalf of iCAD, Inc.
Jeremy Feffer, (212) 915-2568